Articles

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Auckland Cancer Society Research Centre, University of Auckland, NZ, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Auckland Cancer Society Research Centre, University of Auckland, NZ, USA
Proacta Inc., La Jolla, CA, USA
Proacta Inc., La Jolla, CA, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 100 No. 7 (2015): July, 2015 https://doi.org/10.3324/haematol.2014.118455